Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) and Motus GI (NASDAQ:MOTS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Risk & Volatility
Lyra Therapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
Insider & Institutional Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 20.1% of Motus GI shares are held by institutional investors. 17.4% of Lyra Therapeutics shares are held by company insiders. Comparatively, 0.3% of Motus GI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyra Therapeutics | $1.82 million | 8.05 | -$62.68 million | ($1.20) | -0.20 |
| Motus GI | $319,000.00 | 0.45 | -$12.87 million | ($15.64) | 0.00 |
Motus GI has lower revenue, but higher earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Lyra Therapeutics and Motus GI, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 4 | 1 | 0 | 2.00 |
| Motus GI | 0 | 0 | 0 | 0 | N/A |
Lyra Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 1,773.44%. Given Lyra Therapeutics’ higher possible upside, equities research analysts plainly believe Lyra Therapeutics is more favorable than Motus GI.
Profitability
This table compares Lyra Therapeutics and Motus GI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | -5,570.88% | -102.22% | -57.77% |
| Motus GI | -3,239.75% | -1,731.08% | -115.99% |
Summary
Lyra Therapeutics beats Motus GI on 9 of the 13 factors compared between the two stocks.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
